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ABSTRACT
Fusion proteins, comprising peptides deriving from
the translation of two parental genes, are produced
in cancer by chromosomal aberrations. The ex-
pressed fusion protein incorporates domains of both
parental proteins. Using a methodology that treats
discrete protein domains as binding sites for spe-
cific domains of interacting proteins, we have cat-
aloged the protein interaction networks for 11 528
cancer fusions (ChiTaRS-3.1). Here, we present
our novel method, chimeric protein–protein inter-
actions (ChiPPI) that uses the domain–domain co-
occurrence scores in order to identify preserved in-
teractors of chimeric proteins. Mapping the influ-
ence of fusion proteins on cell metabolism and path-
ways reveals that ChiPPI networks often lose tumor
suppressor proteins and gain oncoproteins. Further-
more, fusions often induce novel connections be-
tween non-interactors skewing interaction networks
and signaling pathways. We compared fusion protein
PPI networks in leukemia/lymphoma, sarcoma and
solid tumors finding distinct enrichment patterns for
each disease type. While certain pathways are en-
riched in all three diseases (Wnt, Notch and TGF ),
there are distinct patterns for leukemia (EGFR signal-
ing, DNA replication and CCKR signaling), for sar-
coma (p53 pathway and CCKR signaling) and solid
tumors (FGFR and EGFR signaling). Thus, the ChiPPI
method represents a comprehensive tool for study-
ing the anomaly of skewed cellular networks pro-
duced by fusion proteins in cancer.
INTRODUCTION
Fusion proteins or chimeras in cancers are usually produced
by chromosomal translocations and incorporate parts of
two different parental proteins (1). Fusions often function
as oncoproteins or cancer drivers (2,3). One of the best-
known examples is the BCR/ABL fusion protein, consid-
ered to be the primary oncogenic driver of chronic myeloge-
nous leukemia (4). The identification of this specific fusion
event led to the development of a drug (Imatinib/Gleevec)
that is highly specific for inhibiting the fusion kinase, re-
sulting in a breakthrough treatment for a poorly respon-
sive disease (5). More recently, gene fusions in solid tu-
mors and in prostate cancer in particular have been shown
to drive carcinogenic processes such as invasiveness (e.g.
the TMPRSS2/ERG fusion) (6–8). Thus, gene fusions are
being recognized as important diagnostic and prognostic
biomarkers inmalignant hematological disorders and child-
hood sarcomas (2,3,9,10).
The organization of proteins into groups and networks
due to physical interactions with each other has led to the
discovery of numerous functions of otherwise anonymous
proteins (11). For example, the physical interaction between
transcription factors and non-DNA binding cofactors led
to the understanding that the latter may often be assigned
the role of co-activator or co-repressor (12). In an attempt
to provide a comprehensive list of interactions that govern
the biological processes in a cell, high-throughput protein
interaction assays have been developed with great success.
However, the large-scale sets of interactions, represented as
protein–protein interaction (PPI) networks that are often
analyzed by mathematical methods for comprehensive bio-
logical interpretation, have only been applied to the normal
form of a protein (11,13–24). Furthermore, the question of
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the straightforward prediction of the PPIs of fusion proteins
has not been yet systematically addressed.
PPI network analysis has been effectively used to high-
light the role of cancer driver genes in disrupting the nor-
mal regulation of cellular processes (25–28). These analyti-
cal methods score the tendency of the fusion parental genes
in their cancer-mutant form to induce changes in protein
networks. However, only a few attempts have been made
to study the PPI network properties of fusion genes (as a
hybrid of two genes) (27,29–31). In a recent most compre-
hensive study, Latysheva et al. (32) used a fusion network
approach to reveal that certain parental proteins of fusions
occupy central positions in PPI networks losing their func-
tional activities following fusion events in cancer as well as
that fusions escape regulation by losing post-translational
modification sites.
To demonstrate the systematic identification of PPI of
fusions, uncovering their influence on networks and thus
on cancer phenotypes, we present here chimeric protein–
protein interaction (ChiPPI) method. It uses a ‘domain–
domain co-occurrence’ (DDCOS) score to calculate PPI
likelihood. The DDCOS score is based on the previous ob-
servations about the preference of domain–domain inter-
actions and the co-occurrence methods (33–36). The final
score for a fusion protein and its interactors combines all
the preserved domains of two parental proteins of the fu-
sion. As the result, our method predicts the differences in
networks of the fusion protein in the context to its two
parental proteins (and their preserved protein domains).
ChiPPI differs from current methods in that most meth-
ods utilize a simple ‘unification’ of the PPI networks of
the parental proteins, but are not able to accurately eval-
uate ‘missing’ and ‘preserved’ interactions that result from
the domains of a fusion (27,32). Nevertheless, ChiPPI finds
‘missing’ and ‘preserved’ interactors of a fusion based on
the preserved protein domains of the parental proteins.
We applied ChiPPI to the analysis of 11 528 fusions from
ChiTaRS-3.1 (37), accurately mapping alterations in net-
work properties that delineate the fusion protein network
from parental networks.
Thus, using ChiPPI, we found a loss of tumor sup-
pressors from fusion protein networks and the novel in-
clusion of oncoproteins. We further tested the power
of ChiPPI to resolve differences in cellular metabolism
and pathways (enrichment) in different cancer types, i.e.
leukemia/lymphoma, sarcoma and solid tumors.While cer-
tain pathways are enriched in all three cancer types (Wnt,
Notch, andTransforming-Growth-Factor beta (TGFB) sig-
naling pathway), there are distinct patterns for leukemia
(p53 pathway, Epidermal Growth Factor Receptor (EGFR)
signaling, DNA replication and Cholecystokinin Receptor
(CCKR) signaling), for sarcoma (p53 pathway and CCKR
signaling) and solid tumors (Fibroblast Growth Factor Re-
ceptor (FGFR) and EGFR signaling). Therefore, ChiPPI is
a comprehensive method for analyzing protein fusion net-
works and our results show that it is particularly useful to
uncover remodeling of the PPI networks in different cancer
phenotypes.
MATERIALS AND METHODS
Datasets of cancer fusions
In order to study the fusion networks we used a dataset of
358 cancer fusions of 337 genes from the study ofMitelman
et al. (10) as a training set and the Breakpoints Collection
of 11 528 fusions of the ChiTaRS-3.1 database (37) as a test
set. In addition, we downloaded the COSMIC datasets of
all point mutations in human genes in cancers (38).We used
cBioPortal (http://www.cbioportal.org/public-portal/index.
do) to study the number of patients where cancer-associated
mutations and mutated genes have been detected (Supple-
mentary Table S1). We downloaded the BioGrid database
(http://thebiogrid.org/download.php) of PPIs (39), consist-
ing of 16 102 genes and 218 979 molecular interactions, for
the DDCOS analysis of human genes (Supplementary Ta-
ble S1 and Supplementary Data). For every new release of
the BioGrid database (39), we update the ChiPPI collection
automatically.
Enrichment analysis
The enrichment analysis was performed to determine which
pathways are over-represented, rendering a significant P-
value < 1E-4. This analysis was carried out using GSEA
(40) and PANTHER (41) methods for every set of 50 fusion
networks found in leukemia/lymphoma, sarcoma or solid
tumors (totally 150 networks). Finally, the pathways enrich-
ment analysis was performed using the hypergeometric dis-
tribution as follows: given an input list of proteins, a com-
parison is done considering a number of proteins involved
in a certain pathway or PPI network using the Benjamini–
Hochberg false discovery rate (FDR) adjustment that gives
us a list of pathways for an FDR of 1% (Supplementary Ta-
ble S2).
Domain–domain co-occurrence table
We took all human proteins and determined their pro-
tein domains (from the set of more than 1000 different
known protein domains) in PFAM (42,43), STRING (44)
and ELM (45,46) and other resources (Supplementary Ta-
ble S3 and Supplementary Data).We then used the BioGrid
database of PPIs (39) to ascribe specific domains to known
PPI events (Figure 1). Thus, we built the domain-domain
co-occurence (DDCOS) table, T(x, y), using the PPI net-
works of all the proteins, where x and y are protein do-
mains (Figure 1). It combines frequencies, F(x, y), to iden-
tify how often domain, x, co-occurred with domain, y. To
normalize for domain over- or under-representation across
the proteome, we calculated F(x) and F(y) as frequencies of
domain x and domain y correspondingly throughout all hu-
man proteins. Thus, to determine whether two domains are
frequently found in pairs of interacting proteins in different
PPI events, we calculated a log-odds score as follows:
DDCOS(domain(x), domain(y)) = log
(
Fobserved(domain(x) ∧ domain(y))
Fobserved(domain(x)) ∗ Fobserved(domain(y))
)
(1)
where Fobserved(domain(x)) is an observed frequency
of a particular domain x in all human proteins,
Fobserved(domain(x) ∧ domain(y)) is an observed fre-
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Figure 1. The domain–domain co-occurrence (DDCOS) table. Generation of a proteome-wide database of interactions between discrete protein domains,
followed by determining their protein domains and finally building the DDCOS table using all the interactors in the BioGrid database (39).
quency of the DDCOS of domain(x) and domain(y) in two
interactors as previously described in (48–50).
Scoring chimeric protein–protein interaction (ChiPPI) events
To evaluate an interaction between two proteins we used the
following interaction score (Int):
Int(protein1, protein2) =
∑
every domain x of protein1,
every domain y of protein2
DDCOS(domain(x), domain(y)) (2)
where DDCOS(domain(x), domain(y)) is the DDCOS
score for domains x of protein1 and domain y of protein2
calculated by formula [1].
To set a threshold for Int values that represent bona
fide data-supported interactions, we studied the distribu-
tion of interaction scores for 100 000 randomly selected
pairs of real interactors and 100 000 random pairs of non-
interactors (Supplementary Table S5 and 6; Supplementary
Data). These random datasets have been utilized to verify
the score threshold at 1% FDR. We selected PPIs that oc-
cur in well-known cancer pathways, using different score
thresholds. For each fusion protein of interest, we predicted
all the protein domains associated with the corresponding
fusion protein sequence, using a Hidden Markov Model-
based method, HMMer (51). To build PPI networks for the
fusion protein we first ‘unified’ all the interactors of the par-
ent proteins from BioGrid (39). Next, using the DDCOS
scores we calculated the Int score for every protein interac-
tor and the fusion. Thus, for every PPI event we determined
whether it is maintained or lost upon fusion, using the Int
score threshold at 1%FDR (see examples in Supplementary
Table S4 and Supplementary Data). Finally, we also used
the clustering coefficient as a measure of centrality that cal-
culates a number of triangles in the ChiPPI network of a
fusion. The clustering coefficient was calculated as an aver-
age of the local clustering coefficients of all the nodes in the
ChiPPI network, based on the local clustering coefficient
for each node that was calculated as follows:
C(i) = Ntriangles(i)/Ntriplets(i) (3)
where Ntriangles(i) is a number of connected triangles around
node i and Ntriplets(i) is a number of triplets centered around
node i in the ChiPPI network.
RESULTS
ChiPPI is based on the assumption that PPIs can be approx-
imated by calculating the propensity of discreet domain–
domain interactions. Accordingly, we posed that each PPI
Figure 2. The computing steps that have been done to generate a
proteome-wide scoring system for all the ChiPPI interactions using dis-
crete protein domains.
can be converted into a corresponding set of pairwise–
domain interactions. To generate a proteome-wide scoring
system for interactions using discrete protein domains, we
devised the process described on Figure 2 and explained be-
low in details.
Fusion network construction
Having built a table of the biologically feasible DDCOS
between protein domains throughout the human proteome
(Figure 1), we then built a network that best predicts the
PPIs for each particular fusion protein (Figure 2), as fol-
lows:
i) We unified all the interactors of both parental proteins;
ii) We removed ‘missing’ interactors, lost presumably due to
deletion of parental protein domains (having an Int score
less than the threshold value);
To match this theoretical prediction with experimental
data, we tested how many interactors were missed in any
computed pair (from the 358 fusions in the training set), as
compared to the published data. To do this, we generated
using the DDCOS table four sets of interacting proteins for
each of the 358 fusions, using the Int score thresholds: 0,
0.5, 1.0 and 5.0. While threshold score 5.0 lost many bona
fide interactors, a 0.5 threshold resulted in 99% of the real
cases being included (Supplementary Table S6 and Supple-
mentary Data).
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We manually verified an existence of every interac-
tor in the 50 fusions’ networks using previously pub-
lished information on the experimentally verified interac-
tors (2,3,9,10,52,53). In this way, the correct threshold for
every fusion network was fixed as the percentage of cor-
rectly verified interactors at 1% FDR (P-values adjusted
using the Benjamini–Hochberg procedure) (Supplementary
Table S6 and Supplementary Data). For more than 95% of
fusions, the correct interactors were found for Int scores >
0.5. Therefore, this threshold was used for our fusion net-
work analysis (Supplementary Table S7 and Supplementary
Data). As a result, to construct any fusion network, we re-
moved nodes that were characterized by Int ≤ 0.5, which
we defined as the ‘missing’ interactors (consistent with the
missing domains of the parental proteins).
To study the fusion network properties and their highly
connected parts, we transformed the protein interaction
network to a graph-based format. For example, the highly
connected PPI sub-networks of BCR and ABL1 are dis-
tinct from each other and from that of the BCR/ABL1
fusion protein (Figure 3) based on the predicted domains
in the interacting proteins, our DDCOS analysis and sub-
networks (Int score > 0.5, FDR <1%). While ChiPPI was
primarily designed to identify interactors that are lost from
networks upon protein fusion, we found that ChiPPI also
identified five ‘preserved’ interactors in the networks (in
comparison to the network of ABL1 protein): CRKL,
JAK2, RASA1, CD2AP and INPPL1 (Figure 3). Inclu-
sion of new interactors into the BCR/ABL network is
likely to promote the disease phenotype, since CRKL and
RASA1 regulate tumorigenic signaling in chronic myeloid
leukemia (4,54), JAK2 mutation and fusion is tumori-
genic in myeloproliferative disorders and in acute myeloid
leukemia (AML) (52,54) and CD2AP and INPPL1 are sus-
pected oncogenes involved in segmental glomerulosclero-
sis type 3 and Metabolic Syndrome (52–54), all of which
potentially represent drug targets in disease therapy (Fig-
ure 3). In general, all interactors in the fusion networks
were extended (‘preserved’) set of all interactors from both
parental proteins (with the exception of missing interac-
tors), as well as new interactors at occurrence of new pro-
tein fusion domains. For example, we can observe the new
domains in the fusions as follows: ESTid=L22179.1 (the
KMT2A/AFF1 fusion in ChiTaRS-3.1 (37)) has seven new
domains (Actin, Vfa1, Ery res leader2, Filament head,
YL1, DUF3446 and HPS3 Mid), which were not in the
parental proteins KMT2A andAFF1. Thus, DDCOS anal-
ysis by ChiPPI can be used to identify novel suspect onco-
genes and potential drug targets, as ‘preserved’ interac-
tors in the cancer fusion PPI networks (comparing to the
parental PPI networks).
Comparison between the parental PPI networks and the fu-
sion PPI networks
The underlying question in studying cancer fusion proteins
is: what is their carcinogenic function that is selected for?We
applied ChiPPI to study how fusions can distort parental
protein PPI networks, leading to cell deregulation. Com-
pared to point mutations, insertions and deletions, it is clear
that fusion events can delete functions from the protein (e.g.
loss of a regulatory domain or interaction with an oncopro-
tein), as well as generate a partial fusion of the parental PPI
networks, bringing together proteins that normally never
meet (Figure 4).
To study how networks change between the parental and
fusion networks, we used graph theory to represent the bi-
ological networks of the fusions and the following graph
properties: the node degree, closeness and betweenness. We
compared the networks of the 337 genes that participate
in the 358 fusions (10) with those of 300 genes frequently
mutated in cancer and, used as a control, a set of 300 ran-
domly selected genes. Centrality analysis showed that fu-
sion parental proteins tend to have much higher total de-
gree centrality (P-value< 6.3E-6, theWilcoxon signed-rank
test) and higher betweenness centrality (P-value < 1.3E-
4) than all genes in the control sets (Supplementary Table
S8 and Supplementary Data). Thus, Figure 5 shows that
parental genes found in different cancer phenotypes, e.g.
leukemia, sarcoma and solid tumors, in ChiPPI networks
have higher clustering coefficient than their corresponding
fusions. Therefore, ChiPPI uncovers that parental genes in
fusions are hubs in biological networks prior to the fusion
event, as has also been suggested in a recent study by Laty-
sheva et al. (32). Consequently, fusions reduce the radius of
the protein interaction networks by connecting previously
non-connected parts and reduce the network betweenness
centrality.
We then asked whether fusion events in cancer act to
deregulate the general organization of the cellular PPI net-
work.We found that by connecting all 337 proteins involved
in the 358 fusions in our training dataset, three large con-
nected clusters of genes are formed, with each cluster being
typically involved in a morphologically distinct tumor type
(10). Interestingly, we found that these three clusters are
connected in one highly joined cancer network with some
nodes that are frequently found in many distinct PPI net-
works (Figure 6). Particularly, the Human DNA topoiso-
merase I (Top1) that is a validated target for the treatment
of human cancers (colored in red, Figure 6) is the most con-
nected gene in the network. Other most connected genes
are, for example, found in AML (CREBBP, EP300, NPM1,
Figure 6), in sarcoma (FUS, Figure 6), in renal cell carci-
noma (NONO, Figure 6). As it can be seen from Figure 6, a
large sub-network (left) includes hematological ETV6, IGH
and NUP98 fusions, with the mainly lymphoma-associated
BCL6 fusions as well as epithelial RET fusions (56). The
upper right network (Figure 6) includes the lymphoma-
associated ALK fusions, the carcinoma-associated tran-
scription factor for IGHM, the enhancer 3 (TFE3) fusions
and the sarcoma-associated EWSR1 fusions. The lower
right network (Figure 6) contains mainly hematological
MLL fusions connected to HMGA2 fusions that are typ-
ically found in solid tumors (9,10,56–59). Taken together,
these results indicate that parental proteins in fusions are
indeed central nodes in the PPI networks (32) and they pro-
duce together one highly connected large cancer PPI net-
work that unify different cancer-associated nodes within
different cancer phenotype.
If a fusion event occurs between two proteins in non-
connected PPI networks then we might expect that the two
networks will now be brought close together (Figure 4).
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Figure 3. The protein–protein interaction (PPI) networks of the BCR/ABL fusion and two parental proteins, which show alterations. (A) The ABL1
highly connected disease module. (B) The BCR highly connected disease module. (Note only the closest interactors are shown here). (C) The BCR/ABL1
PPI disease module contains five additional nodes: CRKL, JAK2, RASA1, CD2AP and INPPL1, where CRKL and RASA1 oncogenes are involved
in the developing of CML, JAK2 is associated with acute myeloid leukemia (AML), and CD2AP and INPPL1 are suspected oncogenes, involved in
segmental glomerulosclerosis type 3 and Metabolic Syndrome, respectively. Moreover, some genes are involved in mental diseases (colored in yellow),
immunodeficiency (green), suspected oncogenes in few cancers (blue) and oncogenes (red).
However, if both proteins are in the same PPI network (e.g.
BCR and ABL), then the effect of a fusion event could be
2-fold: loss of interactions through deletion of protein do-
mains in the fusion and enhanced activity of the fusion.
Particularly, we used ChiPPI to systematically analyze net-
work changes in known cancer fusion events. Specifically,
we analyzed the parental proteins of 2632 fusions from the
ChiTaRS-2.1 database (57) finding that 886 fusions (34%)
incorporate parental genes which are already closely associ-
ated in the same PPI network, while the majority (66%) link
previously non-associated networks (Supplementary Table
S9 and 10 and Supplementary Data). We studied PPI net-
works of these fusions and identified potential ‘missing’
proteins from the networks (Supplementary Table S9 and
Supplementary Data). Thus, we found that all fusions in-
corporating such parental proteins which are interactors,
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Figure 4. Cancer fusions make interactors of gene1 and gene2 to be ‘close’ interactors with shorter pathways. (A) Interactors of gene1 are depicted in blue
and interactors of gene2 are in green. (B) Interactors of a fusion of gene1 and gene2. The red colored line shows the fusion of gene1 and gene2. (C) A
shortest distance between interactors of gene1 and gene2 may have different distributions. (D) After a fusion event, the interactors of gene1 and gene2 have
a shortest distance of 1.
Figure 5. The centrality analysis for 337 parental genes in the 358 fusions in the training set (10). The analysis showed that the parental proteins of fusions
tend to have much higher clustering coefficient (P-value < 2.7E-4, the Wilcoxon signed-rank test) than all other genes in the network. Moreover, parental
genes found in leukemia, sarcoma and solid tumors in ChiPPI networks show a similar property, namely, parental genes are central nodes in the PPI
networks.
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Figure 6. Among the 358 fusions, 90% of proteins form three clusters of proteins involved in morphologically distinct tumor types. Highly frequent 158
genes found in highly connected sub-networks of the 358 fusions. The dash line means the score is ‘NA’ because the involved genes are not characterized
by well-known protein domains. The frequency is presented as a heatmap from a red color (highly frequent), to green (less frequent).
change PPI networks of parental proteins in order to reduce
a number of interactors (e.g. radius) in the ChiPPI network
in order to enhance activity of the fusions (Supplementary
Table S10 and Supplementary Data).
Fusion networks frequently lose tumor suppressors
We speculated that the fusion of two proteins within the
same PPI network has a dual function: the loss of inter-
actors in the same PPI (e.g. removal of a tumor suppres-
sor) (Supplementary Table S10 and 11 and Supplementary
Data), while bringing closer other interactions (for exam-
ple, enhancing the activity of a signaling pathway). How-
ever, when two non-connected PPI networks are joined by
a fusion event it is not clear whether there will be loss of tu-
mor suppressors from the fusion network. To test this, we
used ChiPPI to rebuild the PPI networks of 11 528 fusion
proteins (ChiTaRS-3.1 (37)) and analyzed the proteins fre-
quentlymissing from the networks (using our previously de-
scribed procedure). In most networks, we found that more
than five tumor suppressors aremissing from the interactors
because of a loss of the functional domains in the fusions
(Supplementary Table S1 and Supplementary Data). The
most frequently lost tumor suppressors in all cancers are
TP53,HDAC3, PML, SMAD3/SMAD2,RB1 andBRCA1
(Supplementary Table S1 and Supplementary Data) and in
fusion networks this is also the case, indicating that fusion
events might be specifically selected for due to the loss of
the tumor suppressors. To directly compare the association
of fusion events or other types of mutation to loss of tumor
suppressors from PPI networks, we took 572 cancer genes
from the COSMIC database (38) that are causally linked
to cancer mutations and asked what changes occur to tu-
mor suppressors in their corresponding PPI networks upon
gene mutation (Supplementary Table S1 and 2 and Supple-
mentary Data). We first mapped the PPI network for each
wild-type protein, followed by mapping the cataloged mu-
tations to specific protein domains within the 572 proteins.
Finally, we built a new PPI network for the mutant protein
by subtracting themutant domain from the interactionmap
of the wild-type protein. The resultant maps for 572 mutant
PPI networks revealed a loss of at least 10 interactors per
protein due to mutated domains (Supplementary Table S9
and 10 and Supplementary Data). While analyzing the pre-
dicted or known function of these lost interactors we found
that 25% percent were classified as tumor suppressors, sig-
nificantly different from the random controls (FDR< 1%,
P-value ≤ 3E-4, the Wilcoxon signed-rank test). Further,
the rate of loss of tumor suppressors from mutant gene PPI
networks was found to be similar to that of fusion gene PPI
networks (25% compared to 20%, respectively). Taken to-
gether, these results indicate that while the mechanistic as-
pect of fusion events as well as other forms of deleterious
mutation in cancer appears to be complex, the same final re-
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sult is observed, namely, the loss of tumor suppressors from
the PPI networks.
Pathway enrichment of ChiPPI networks delineates between
leukemia, sarcoma and solid tumor
Having shown that fusions dramatically skew PPI networks,
we next asked if these network aberrations are associated
with particular signaling pathways in different cancer types.
First, we classified all 358 fusions (10) into three disease
types: leukemia/lymphoma, sarcoma or solid tumors. This
resulted in 238 characterized fusions for leukemia, 51 for
sarcoma and 69 for solid tumors (in our training set). Then
we performed a pathway enrichment analysis of all the
interactors for every ChiPPI network, in order to iden-
tify over-represented (cancer-associated) pathways. Next,
we analyzed the remaining fusions in ChiPPI (∼11 000)
and their PPI network members, for pathway enrichment,
finding that once again, three distinct groups are formed.
While certain pathways are enriched in all three diseases
(Wnt, Notch and TGF ), there are distinct patterns for
leukemia (p53 pathway, EGFR signaling, DNA replica-
tion and CCKR signaling), for sarcoma (p53 pathway and
CCKR signaling) and solid tumors (FGFR and EGFR sig-
naling) (P-values are all < 1.0E-6) (Figure 7, Supplemen-
tary Figure S1–8 and Supplementary Data), leading us to
hypothesize that (i) fusion events are selected for based on
specific pathway activation, and (ii) different cancer types
rely on specific combinations of altered pathways. Reassur-
ingly, pathway enrichment analyzes of fusions using ChiPPI
closely matches previous pathway enrichment studies (33).
Thus, in leukemia KEGG analysis revealed Notch, TGF-
, ErbB, MAPK, Jak- STAT, Wnt, T-cell receptor and B-
cell receptor pathway activation (58,59) (Figure 7). Partic-
ularly, Supplementary Figure S9 represents the enrichment
results for fusion transcripts from different leukemia and
lymphoma types that shows unique profiles for the leukemia
and lymphoma sub-types. Taken together, these results indi-
cate that pathway enrichment specific for fusions follows a
similar pattern to total pathway activity in the studied can-
cer types.
DISCUSSION AND CONCLUSION
Overview
In this paper we present ChiPPI, (Figure 8, The ChiPPI in-
terface), a novel approach implemented in an openly acces-
sible web-server, for performing a global analysis of changes
to PPI networks upon protein fusion events in cancer. We
have analyzed the largest number of fusions known today
(11 528 fusions, ChiTaRS-3.1) (37). We have compared the
PPI networks of fusion proteins with the protein PPI net-
works of both parental proteins, and have mapped addi-
tional (non-fusion) cancermutations to parental proteins or
to other proteins that coincide in the fusion protein PPI net-
work. This computational methodology successfully iden-
tifies the changes induced to the known chimeric PPI net-
works. For the specific set of protein fusion events unique to
cancer cells the methodology described here appears to ac-
count for most of the known protein interaction perturba-
tions upon gene fusion. While it is possible, and even likely,
that we have ruled out certain real changes to PPI networks
due to the presence or absence of promiscuous domains in
the fusion proteins. This model can provide novel insight
on cancer cell physiology. For example, using ChiPPI anal-
ysis of over 2000 fusions we were able to identify missing
tumor suppressors from the fusion networks. Thus, ChiPPI
provides a predictive model for demonstrating how fusions
may act as drivers of cancer by reducing or losing interac-
tions with tumor suppressors in PPI networks.
Comparison to other methods
To verify the DDCOS scoring system of ChiPPI, we com-
pared it with IDDI (60), Domine (61) and iPFAM (62).
The difference between ourChiPPImethod and othermeth-
ods is that we predict interactors of fusions while the other
methods predict interactors of normal proteins only (63).
We found that ChiPPI includes ten times more DDCOS
cases than other methods. The reason being, that IDDI
has∼204 705 domain–domain interactions (last updated in
May, 2011) while Domine has 20 513 domain–domain in-
teractions (last updated in September, 2010). In ChiPPI, we
used the DDCOS table of size equals to 9380 * (9380−1)/2
= 43 987 510 domain–domain interactions, where 9380
is amount of various unique domains for all interactors
from BioGrid (39). Thus, by comparison, ChiPPI has more
domain–domain interactions (∼200-fold more than IDDI),
giving it its distinct advantage over other methods (Table 1).
Taking into consideration normal proteins, we found that
our scoring system is in good agreement with these three
published methods (Pearson correlation coefficient is 0.57,
0.56 and 0.64 for the top 100 scores of IDDI) (60), Domine
(61) and iPFAM (62) respectively (Table 1, Supplementary
Table S12 and Supplementary Data). Those results indicate
that ChiPPI is a reliable tool for studying PPI events for nor-
mal as well as for fusion networks.
Mapping PPI networks of cancer fusions
We applied ChiPPI to the analysis of 11 528 fusions
from ChiTaRS-3.1 (37), accurately mapping alterations in
network properties that delineate the fusion protein net-
work from parental networks. We ranked the PPI-pathway
associations with respect to a distribution obtained for
the real interactions versus random datasets. Based on
these data, we compared cellular pathways ‘enrichment’ in
leukemia/lymphoma, sarcoma and solid tumors, for each
cancer fusion protein. While a set of core pathways is en-
riched in all three cancer types, i.e. Wnt, Notch and TGF
, there is also a set of pathways specifically affected by fu-
sions, in leukemia, i.e. p53 pathway, EGFR signaling, DNA
replication and CCKR signaling; sarcoma, i.e. p53 path-
way and CCKR signaling; and solid tumors, i.e. FGFR
and EGFR signaling. Our findings fit well with previous
observations on pathways enrichment in cancer based on
the analysis of mutation load or altered gene expression
(33,47,55,59,64) leading us to speculate that both fusion
events and other types of alterations, including mutation
and gene expression alterations, are similarly selected for in
cancer and they might be mediated by network aberrations
affecting similar pathways. Finally, using ChiPPI, we found
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Figure 7. The comparison between the pathways enrichment in leukemia/lymphoma, sarcoma and solid tumors. There is a different pattern of the en-
richment. The pathways enriched in leukemia are: Wnt Signaling (P-value = 2.24E-16), p53 pathway (P-value = 1.95E-10), Notch signaling (P-value =
2.95E-09), EGFR signaling (P-value = 2.31E-08), DNA replication (P-value = 9.81E-07), TGF- signaling (P-value = 1.95E-06) and CCKR signaling
(P-value = 2.30E-06). The pathways enriched in sarcoma are: Notch signaling (P- value = 8.48E-14), TGF- signaling (P-value = 3.01E-10), p53 path-
way (P-value = 7.31E-09), Wnt signaling (P-value = 2.32E-08) and CCKR signaling (P-value = 8.48E-07). The pathways enriched in solid tumors are:
FGFR signaling (P-value= 6.32E-15), EGFR signaling (P-value= 2.13E-11), TGF- signaling (P- value= 2.20E-07),Wnt signaling (P-value= 2.24E-06)
and Notch signaling (P-value = 8.48E-06).
Table 1. The methods comparison with ChiPPI
ChiPPI (last updated
September, 2016)
IDDI (last updated
May, 2011)
DOMINE (last
updated September,
2010)
iPFAM (last updated
August, 2013) Latysheva et al. (27)
Domain–domain
Interactions
43 987 510 204 705 20 513 9500 <1000
Number of domains 16 953 7351 5410 16 640 <2000
Number of fusions 23 141 NO NO NO 2699
that tumor suppressors are lost from fusion networks, while
oncoproteins are maintained and even brought into closer
proximity with other network members. Therefore, ChiPPI
provides a comprehensive method for analyzing protein fu-
sion networks and can be successfully utilized to uncover
dramatic changes in the cancer cellular PPI networks.
Detailed investigation of individual fusion events are es-
sential to distinguish other effects such as changes in tissue
specificity (65) that may give rise to new functions that are
not present in the individual parental proteins, or to deter-
mine whether the fusion is simply an elaborate way of intro-
ducing a truncating stop codon. To conclude, the ChiPPI
results suggest a new role for fusions proteins as hubs in
cancer interaction networks, confirming previous studies
(27,66). Identifying drugable targets in the cancer networks
skewed by the introduction of fusion proteins may lead to
the discovery of new fusion-specific anti-cancer drugs in the
future.
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Figure 8. The interface of ChiPPIwith querying and analysis features. The fusion networks can be searched usingwhatever two protein names or fusion IDs.
The interactions can be visualized in the form of different layouts like Tree, Circle, Radial and Force Directed. Various network properties can be studied,
such as a number of interacting pairs, oncoproteins, affected interactors, missing interactors, the diameter, clustering coefficient and centrality measures.
Finally, for each interaction, cross-links are present for databases like ChiTaRS, Pfam, InterPro and SMART. The statistics part and the network structure
information also appears on the ChiPPI website at the bottom.
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